User menu

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Bibliographic reference ; Wiendl, H ; Toyka, K V ; Rieckmann, P ; Gold, R ; et. al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.. In: Journal of neurology, Vol. 255, no.10, p. 1449-63 (2008)
Permanent URL http://hdl.handle.net/2078.1/125004
  1. MSTCG, et al. (2004) Escalating immunotherapy of multiple sclerosis – New aspects and practical application. J Neurol 251:1329–1339
  2. MSTCG, et al. (2006) Symptomatic Treatment of Multiple Sclerosis. Eur Neurol 56:78–105
  3. Goodin D. S., Frohman E. M., Garmany G. P., Halper J., Likosky W. H., Lublin F. D., Silberberg D. H., Stuart W. H., van den Noort S., Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, 10.1212/wnl.58.2.169
  4. McDonald W, Compston A, Edan G, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
  5. Dalton C, Dalton CM, Brex PA, et al. (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52:47–53
  6. Tintore M, Rovira A, Río J, et al. (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60:27–30
  7. Polman CH, Wolinsky JS, Reingold SC (2005) Multiple sclerosis diagnostic criteria: three years later. Mult Scler 11:5–12
  8. Polman CH, Reingold SC, Edan G, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846
  9. Wiendl H, Kieseier BC, Gold R, et al. (2006) Revision der neuen McDonalds Kriterien zur Diagnose einer MS. Nervenarzt 77:1237–1245
  10. Berger T, Rubner P, Schautzer F, et al. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139–145
  11. Gaertner S., de Graaf K. L., Greve B., Weissert R., Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis, 10.1212/01.wnl.0000147259.34163.33
  12. Lampasona V., Franciotta D., Furlan R., Zanaboni S., Fazio R., Bonifacio E., Comi G., Martino G., Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects, 10.1212/01.wnl.0000127615.15768.ae
  13. Rauer S, Euler B, Reindl M, Berger T (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 77:739–742
  14. Kuhle J, Lindberg RL, Regeniter A, et al. (2007) Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 356:371–378
  15. Lim ET, Berger T, Reindl M, et al. (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 11:492–494
  16. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112
  17. Nakashima I, Fujihara K, Sato S, Itoyama Y (2006) Clinical and MRI features of Japanese MS patients with NMO-IgG. J Neurol Neurosurg Psychiatry 77:1073–1075
  18. Paul F, Jarius S, Aktas O, et al. (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133
  19. Matsuoka T, Matsushita T, Kawano Y, et al. (2007) Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130:1206–1223
  20. Lucchinetti CF, Mandler RN, McGavern D, et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461
  21. Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L (2001) Visual and motor evoked potentials in the course of multiple sclerosis. Brain 124:2162–2168
  22. Kallmann BA, Fackelmann S, Toyka KV, Rieckmann P, Reiners K (2006) Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 12:58–65
  23. Kappos L, Polman CH, Freedman MS, et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249
  24. Anonymus (2006) Europäische Kommission genehmigt Aktualisierung der therapeutischen Indication für Rebif® www.serono.com/content/media/downloads/2006/20060710_de.pdf
  25. Kappos L, Freedman MS, Polman CH, et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389–397
  26. Rio J, Tintoré M, Nos C, et al. (2005) Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 252:795–800
  27. Kinkel RP, Kollman C, O’Connor P, et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:678–684
  28. Pohl Daniela, Rostasy Kevin, Gärtner Jutta, Hanefeld Folker, Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a, 10.1212/01.wnl.0000153570.33845.6a
  29. Ghezzi A, Amato MP, Capobianco M, et al. (2005) Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 11:420–424
  30. Tenembaum SN, Segura MJ (2006) Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 67:511–513
  31. Banwell B, Reder AT, Krupp L, et al. (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66:472–476
  32. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. (2005) Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 65:802–806
  33. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G (2005) The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 65:807–811
  34. Clanet M., Radue E.W., Kappos L., Hartung H.P., Hohlfeld R., Sandberg-Wollheim M., Kooijmans-Coutinho M.F., Tsao E.C., Sandrock A.W., A randomized, double-blind, dose-comparison study of weekly interferon  -1a in relapsing MS, 10.1212/01.wnl.0000032256.35561.d6
  35. Clanet M, Kappos L, Hartung HP, et al. (2004) Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 10:139–144
  36. Freedman MS, Francis GS, Sanders EA, et al. (2005) Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11:41–45
  37. Vartanian T (2003) An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther 25:105–118
  38. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., Monaghan E., Li D., Weinshenker B., Randomized, comparative study of interferon  -1a treatment regimens in MS: The EVIDENCE Trial, 10.1212/01.wnl.0000034080.43681.da
  39. Panitch H, Goodin D, Francis G, et al. (2005) Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 239:67–74
  40. Schwid SR, Thorpe J, Sharief M, et al. (2005) Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 62:785–792
  41. Durelli L, Verdun E, Barbero P, et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453–1460
  42. Koch-Henriksen N, Sørensen PS, Christensen T, et al. (2006) A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66:1056–1060
  43. Bertolotto A (2004) Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 17:241–36
  44. Sorensen P, Koch-Henriksen N, Ross C, et al. (2005) Appearance and disappearance of neutralizing antibodies during interferon beta therapy. Neurology 65:33–39
  45. Sorensen PS, et al. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1191
  46. Sorensen PS, Ross C, Clemmesen KM, et al. (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12:817–827
  47. Polman C, Kappos L, White R, et al. (2003) Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60:37–43
  48. Francis GS, Rice GP, Alsop JC (2005) Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65:48–55
  49. Kappos L, Clanet M, Sandberg-Wollheim M, et al. (2005) Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65:40–47
  50. Koch M, Mostert JP, de Vries JJ, De Keyser J (2007) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 68:1163–1164
  51. Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP (2005) Immune response to immunotherapy: the role of neutralizing antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 4:403–412
  52. Khan Omar A, Zvartau-Hind Marina, Caon Christina, Din Moeen U, Cochran Mickey, Lisak Deena, Tselis Alexandros C, Kamholz John A, Garbern James Y, Lisak Robert P, Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy, 10.1177/135245850100700309
  53. Haas J, Firzlaff M (2005) Twenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 12:425–431
  54. Vallittu AM, Peltoniemi J, Elovaara I, et al. (2005) The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand 112:234–237
  55. Flechter S, Vardi J, Pollak L, Rabey JM (2002) Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 197:51–55
  56. Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M; 9006 Study Group (2007) Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology 68:939–944
  57. Ramtahal J, Jacob A, Das K, Boggild M (2006) Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 253:1160–1164
  58. Ziemssen Tjalf, Neuroprotection and Glatiramer Acetate: The Possible Role in the Treatment of Multiple Sclerosis, Advances in Experimental Medicine and Biology (2004) ISBN:9781461347408 p.111-134, 10.1007/978-1-4419-8969-7_7
  59. Aharoni R, Eilam R, Domev H, et al. (2005) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 102:19045–19050
  60. Khan O, Shen Y, Caon C, et al. (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11:646–651
  61. Wolinsky JS, Narayana PA, O’Connor P, et al. (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61:14–24
  62. Filippi M, Wolinsky JS, Comi G (2006) Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 5:213–220
  63. Simmons DL (2005) Anti-adhesion therapies. Curr Opin Pharmacol 5:398–404
  64. Ropper AH (2006) Selective treatment of multiple sclerosis. N Engl J Med 354:965–967
  65. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63–66
  66. Theien BE, Vanderlugt CL, Eagar T, et al. (2001) Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 107:995–1006
  67. Miller D, Khan OA, Sheremata WA, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23
  68. Rudick RA, Stuart WH, Calabresi PA, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923
  69. Polman CH, O’Connor PW, Havrdova E, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910
  70. Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8:1275
  71. Yousry TA, Major EO, Ryschkewitsch C, et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933
  72. Khalili K, White MK (2006) Human demyelinating disease and the polyomavirus JCV. Mult Scler 12:133–142
  73. Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358:647–648
  74. BI GmbH BI (2008) http://www.biogenidec.com/site/products-on-the-market.html
  75. European Medicines Agency (EMEA) (2008) EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/humandocs/Humans/EPAR/tysabri/tysabri.htm
  76. Ghalie R, Edan G, Laurent M, et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59:909–913
  77. Ghalie R, RG, Mauch E, Edan G, et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8:441–445
  78. Cocco E, Marchi P, Sardu C, et al. (2007) Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 13:975–980
  79. Scott LJ, Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18:379–396
  80. Kappos L, Bates D, Hartung HP, et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431–441
  81. Gold R, Jawad A, Miller DH, et al. (2007) Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187:156–158
  82. O'Connor P. W., Goodman A., Willmer-Hulme A. J., Libonati M. A., Metz L., Murray R. S., Sheremata W. A., Vollmer T. L., Stone L. A., , Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects, 10.1212/01.wnl.0000128136.79044.d6
  83. O’Connor PW, Li D, Freedman MS, et al. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894–900
  84. Kappos L, Antel J, Comi G, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124–1140
  85. Sipe JC (2005) Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 5:721–727
  86. Rose JW, Burns JB, Bjorklund J, et al. (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69:785–789
  87. Bielekova B, Richert N, Howard T, et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Nat Acad Sci USA 101:8705–8708
  88. Rose JW, Watt HE, White AT, Carlson NG (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56:864–867
  89. Hauser SL, Waubant E, Arnold DL, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688
  90. Bar-Or A, Calabresi PA, Arnold D, et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395–400
  91. Coles AJ, Cox A, Le Page E, et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108
  92. Coles AJ, et al. (2007) Efficacy of Alemtuzumab in Treatment-Naive Relapsing-Remitting Multiple Sclerosis: Analysis after Two Years of Study CAMMS223 Neurology (Suppl 1) 68:A100
  93. Hirst CL, Pace A, Pickersgill TP, et al. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 255:231–238
  94. Markovic-Plese S., Bielekova B., Kadom N., Leist T. P., Martin R., Frank J. A., McFarland H. F., Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon  -1b, 10.1212/01.wnl.0000071218.34009.af
  95. Pulicken M, Bash CN, Costello K, et al. (2005) Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 11:169–174
  96. Calabresi P. A., Wilterdink J. L., Rogg J. M., Mills P., Webb A., Whartenby K. A., An open-label trial of combination therapy with interferon  -1a and oral methotrexate in MS, 10.1212/wnl.58.2.314
  97. Jeffery D. R., Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis, 10.1212/wnl.63.12_suppl_6.s41
  98. Smith DR, Weinstock-Guttman B, Cohen JA, et al. (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 11:573–582
  99. Jeffery DR, Chepuri N, Durden D, Burdette J (2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11:296–301
  100. Perini P, Calabrese M, Tiberio M, et al. (2006) Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: A comparative study. J Neurol 253:1034–1040
  101. Sorensen PS (2003) Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Neurol Sci 24(Suppl 4):S227–S230
  102. Achiron A, Kishner I, Sarova-Pinhas I, et al. (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515–1520
  103. Hommes OR, Sørensen PS, Fazekas F, et al. (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149–1156
  104. Soelberg Sorensen P., Haas J., Sellebjerg F., Olsson T., Ravnborg M., , IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS, 10.1212/01.wnl.0000145798.61383.39
  105. Stangel M, Gold R (2005) Intravenous Immunoglobulins in MS. Int MS J 12:5–10,4
  106. Haas J, Hommes OR (2007) A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 13:900–908
  107. Achiron A, Kishner I, Dolev M, et al. (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251:1133–1137
  108. Haas J (2000) High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 6(Suppl 2):S18–S20 and S33
  109. Hartung H, Gonsette R, König N, et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet 360:2018–2025
  110. Krapf H, Morrissey SP, Zenker O, et al. (2005) Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 65:690–695
  111. Avasarala JR, Cross AH, Clifford DB, et al. (2003) Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 9:59–62
  112. Paul F, Dörr J, Würfel J, Vogel HP, Zipp F (2007) Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78:198–200
  113. Edan G, Miller D, Clanet M, et al. (1997) Therapeutic effect of mitoxantrone combined with methylsprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118
  114. Le Page E, Leray E, Taurin G, et al. (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79:52–56
  115. Confavreux C., Saddier P., Grimaud J., Moreau Th., Adeleine P., Aimard G., Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study, 10.1212/wnl.46.6.1607
  116. Massacesi L, Parigi A, Barilaro A, et al. (2005) Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 62:1843–1847
  117. Vermersch P, Stojkovic T, de Seze J (2005) Mycophenolate mofetil and neurological diseases. Lupus 14 (Suppl 1):S42–S45
  118. Frohman EM, Brannon K, Racke MK, Hawker K (2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27:80–83
  119. Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN (2006) Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66:1245–1247
  120. Vollmer T, et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607–1608
  121. Ruprecht K., Klinker E., Dintelmann T., Rieckmann P., Gold R., Plasma exchange for severe optic neuritis: Treatment of 10 patients, 10.1212/01.wnl.0000138437.99046.6b
  122. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC (2006) Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63:930–935
  123. Comi G, Martino G (2006) MS treatment: New perspectives. Clin Neurol Neurosurg 108:339–345
  124. Tomassini V, Paolillo A, Russo P, et al. (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253:287–293
  125. Filippi M, Rocca MA, Arnold DL, et al. (2006) EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 13:313–325